Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

261. Type 2 diabetes as a major risk factor for COVID-19 severity: a meta-analysis Full Text available with Trip Pro

Type 2 diabetes as a major risk factor for COVID-19 severity: a meta-analysis Type 2 diabetes as a major risk factor for COVID-19 severity: a meta-analysis Services on Demand Journal Article Indicators Cited by SciELO Related links Similars in SciELO Share Print version ISSN 2359-3997 On-line version ISSN 2359-4292 Arch. Endocrinol. Metab. vol.64 no.3 São Paulo May/June 2020 Epub June 12, 2020 http://dx.doi.org/10.20945/2359-3997000000256 brief report Type 2 diabetes as a major risk factor (...) of patients as a covariate; there was no impact on our initial results. Figure 1 Forest-plot showing association of diabetes and severity of COVID-19, obtained from7descriptive studies. Diabetes mellitus appears to be a major, age-independent risk factor for severity of COVID-19. Further studies are necessary to address mechanisms by which diabetes may affect the prognosis of COVID-19 and how improving glycemic control might impact the course of the disease. Acknowledgements M.C.B. is the guarantor

2020 Archives of endocrinology and metabolism

262. Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis Full Text available with Trip Pro

Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis DIABETOLOGY / SYSTEMATIC REVIEW/META-ANALYSIS Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis 1 , 1 , 1 , 1 1 Department of General Medicine, The First Affiliated Hospital of Anhui Medical University (...) on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [ ]. A systematic literature search was performed on the major online databases including PubMed, EMBASE and the Cochrane Library to identify related studies published between database inception and October 31, 2018. The literature search items were applied using the following search terms with multiple combinations: (“type 2 diabetes mellitus” OR “T2DM” OR “diabetes type 2” OR “type 2 dm” OR “non-insulin-dependent

2020 Archives of Medical Science

263. Does Consumption of Refined Carbohydrate Predict Incidence of Type Two Diabetes Mellitus? A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Does Consumption of Refined Carbohydrate Predict Incidence of Type Two Diabetes Mellitus? A Systematic Review and Meta-Analysis Does Consumption of Refined Carbohydrate Predict Incidence of Type Two Diabetes Mellitus? A Systematic Review and Meta-Analysis : International Journal of Medicine and Pharmacy Sunday, January 31, 2021 ISSN 2372-5087 (Print) 2372-5095 (Online) DOI: 10.15640/ijmp / / / / / > > Vol 8 No 1 June 2020 Abstract 1 Does Consumption of Refined Carbohydrate Predict Incidence (...) of Type Two Diabetes Mellitus? A Systematic Review and Meta-Analysis Mohammad Mahzari, Abdullah A Mamun Abstract Background: Type two diabetes mellitus (T2DM) is a highly prevalent health disorder among adult males and females worldwide. There is consistent evidence that unhealthy diets and physical inactivity play an important role in the development of T2DM. Many people consume refined carbohydrates as part of their daily meals. However, the evidence on whether refined carbohydrates predict T2DM

2020 INTERNATIONAL JOURNAL OF MEDICINE AND PHARMACY

265. Effectiveness of Dietetic Intervention for People with Type 2 Diabetes: A Meta-Analysis Full Text available with Trip Pro

Effectiveness of Dietetic Intervention for People with Type 2 Diabetes: A Meta-Analysis Effectiveness of Dietetic Intervention for People with Type 2 Diabetes: A Meta-Analysis by George Siopis, Stephen Colagiuri, Margaret Allman-Farinelli :: SSRN Share: Permalink Using these links will ensure access to this page indefinitely Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission (...) highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the period, and our decision to make this a offering, or visit The Lancet´s page, and for any feedback please contact . Effectiveness of Dietetic Intervention for People with Type 2 Diabetes: A Meta-Analysis 39 Pages Posted: 6 Oct 2020 The University of Sydney - Charles Perkins Centre University of Sydney - Boden Institute of Obesity, Nutrition

2020 SSRN Electronic Journal

266. Dulaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Dulaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dulaglutid (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 April 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A20-09 (...) Dulaglutide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (new scientific findings) Extract of dossier assessment A20-09 Version 1.0 Dulaglutide (type 2 diabetes mellitus) 29 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dulaglutide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V Commissioning agency Federal

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

267. Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus

Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus ACE Technology Guidances Dapagliflozin 5 mg and 10 mg tablets, and empagliflozin 10 mg and 25 mg tablets for managing type 2 diabetes mellitus, in the following circumstances:>as a dual therapy in combination with metformin for patients with HbA1c measurement greater than 7% despite treatment with metformin monotherapy; oras a dual therapy in combination with a sulfonylurea for patients with HbA1c measurement (...) May 2017 Last Updated on 01 Sep 2020 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended: Dapagliflozin 5 mg and 10 mg tablets, and empagliflozin 10 mg and 25 mg tablets for managing type 2 diabetes mellitus, in the following circumstances: as a dual therapy in combination with metformin for patients with HbA1c measurement greater than 7% despite treatment with metformin monotherapy; or as a dual therapy in combination with a sulfonylurea for patients

2020 ACE Technology Guidance (Singapore)

268. Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus Full Text available with Trip Pro

Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Review Diabetol Metab Syndr Actions . 2020 May 24;12:45. doi: 10.1186/s13098-020-00551-1. eCollection 2020. Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Internal Medicine Department, School of Medicine, Universidade Federal do Rio Grande do Sul (...) of hyperglycemia in type 2 diabetes mellitus Marcello Casaccia Bertoluci et al. Diabetol Metab Syndr . 2020 . Free PMC article Show details Display options Display options Format Diabetol Metab Syndr Actions . 2020 May 24;12:45. doi: 10.1186/s13098-020-00551-1. eCollection 2020. Authors , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1 Internal Medicine Department, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2350, 4º Andar, Porto

2020 Brazilian Clinical Guidelines

269. A Diabetes Self-Management Education/Support (DSME/S) Program in Reference to the Biological, Psychological and Social Aspects of a Patient with Type 2 Diabetes Mellitus: A Systematic Review Full Text available with Trip Pro

Education Methods on Knowledge, Attitudes and Behaviours of Adult Patients With Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 1–8. https://doi.org/10.1016/j.jcjd.2017.11.003 Albikawi, Z. F., Petro-Nustas, W., & Abuadas, M. (2016). Self-care Management Intervention to Improve Psychological Wellbeing for Jordanian Patients with Type Two Diabetes Mellitus. Issues in Mental Health Nursing, 37(3), 190–201. https://doi.org/10.3109/01612840.2015.1122118 Azami, G., Soh, K. L., Sazlina, S. G., Salmiah (...) , M. S., Aazami, S., Mozafari, M., & Taghinejad, H. (2018). Effect of a Nurse-Led Diabetes Self-Management Education Program on Glycosylated Hemoglobin among Adults with Type 2 Diabetes. Journal of Diabetes Research, 2018, 1–12. Beck, J., Greenwood, D. A., Blanton, L., Bollinger, S. T., Butcher, M. K., Condon, J. E., … Wang, J. (2018). 2017 National Standards for Diabetes Self-Management Education and Support. Diabetes Educator, 44(1), 35–50. https://doi.org/10.1177/0145721718754797 Busch, M

2019 Jurnal Ners

270. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials Full Text available with Trip Pro

Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials | Research Square Browse Tools & Services Your Cart This preprint is under consideration at BMC (...) diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials Jing Qin, Li Song Jing Qin Lanzhou University Second Hospital Li Song Heidelberg University Corresponding Author DOI: License: This work is licensed under a CC BY 4.0 License. The most recent version of this article is available . Abstract Background The cardiovascular effects of glucagon-like peptide-1 (GLP-1) receptor agonists are still controversial in the treatment of type 2 diabetes mellitus (T2DM

2019 Research Square

271. Association between subthreshold depression and self-care behaviours in people with type 2 diabetes: a systematic review of observational studies Full Text available with Trip Pro

in people with type 2 diabetes. Systematic review registration: PROSPERO CRD42018116373 Keywords Subthreshold depression, depression, self-care behaviours, self- management, type 2 diabetes, systematic review Figures Figure 1 Background Methods Results Discussion Conclusions Abbreviations Declarations References Supplementary Files This is a list of supplementary files associated with this preprint. Click to download. Comments (0) Comments can take the form of short reviews, notes or questions (...) is associated with self-care behaviours in adults with type 2 diabetes. Our review established a gap in knowledge and suggests that further high-quality studies are needed to examine the association between subthreshold depression and self-care behaviours in people with type 2 diabetes. Systematic review registration: PROSPERO CRD42018116373 Figures Figure 1 Background Methods Results Discussion Conclusions Abbreviations Declarations References Comments (0) Comments can take the form of short reviews, notes

2019 Research Square

272. Effect of yoga and aerobics exercise on sleep quality in women with Type 2 diabetes: a randomized controlled trial. Full Text available with Trip Pro

Effect of yoga and aerobics exercise on sleep quality in women with Type 2 diabetes: a randomized controlled trial. The aim of this study was investigating the effect of 12 weeks of yoga and aerobic exercise (running on a treadmill) on the sleep quality in women with Type 2 diabetes.39 diabetic women were selected from Semnan city with the mean age of 46.85±3.35 years, weight of 69.79±17.18 kg, height of 155.03±5.00, BMI of 29.64±5.00 kg/m2 who had a background of diabetes for 6.46±2.69 years (...) of aerobic exercise in women suffering from diabetes Type 2. Thus, yoga exercise can be suggested to these patients.

2019 Sleep science (Sao Paulo, Brazil) Controlled trial quality: uncertain

273. Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes. Full Text available with Trip Pro

Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes. To assess the cost-effectiveness of pharmaceutical care (PC) intervention versus usual care (UC) in the management of type 2 diabetes.This study was a randomized, controlled study with a 12-month patient follow-up in two Nigerian tertiary hospitals. One hundred and ten patients were randomly assigned to each of the "intervention" (PC) and the "control" (UC) groups (...) , respectively, with an associated incremental cost-utility ratio of NGN 88,525 ($571) per QALY gained. In the cost-effectiveness acceptability curve, the probability that PC was more cost-effective than UC was 95% at the NGN 250,000 ($1613) per QALY gained threshold and 52% at the NGN 88,600 ($572) per QALY gained threshold.The PC intervention was very cost-effective among patients with type 2 diabetes at the NGN 88,525 ($571.13) per QALY gained threshold, although considerable uncertainty surrounds

2019 Value in health regional issues Controlled trial quality: uncertain

274. The Impact of Pharmaceutical Care Intervention on the Quality of Life of Nigerian Patients Receiving Treatment for Type 2 Diabetes. Full Text available with Trip Pro

The Impact of Pharmaceutical Care Intervention on the Quality of Life of Nigerian Patients Receiving Treatment for Type 2 Diabetes. To evaluate the impact of pharmaceutical care (PC) intervention on health-related quality of life (HRQOL) of patients with type 2 diabetes.This study was a randomized, controlled study with a 12-month patient follow-up. The study protocol was approved by the Research Ethical Committees of the institutions in which this study was conducted. A total of 110 patients (...) or Mann-Whitney U tests for nonnormally distributed data at baseline, 6 months, and 12 months. Comparisons of proportions were done by using the chi-square test.The overall HRQOL (0.86 ± 0.12 vs. 0.64 ± 0.10; P < 0.0001) and single attributes except "hearing" functioning of the patients were significantly improved at 12 months in the PC intervention arm when compared with the UC arm. The HRQOL utility score was highly negatively (deficit ≥10%) associated with increasing age (≥52 years), diabetes

2019 Value in health regional issues Controlled trial quality: uncertain

275. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Full Text available with Trip Pro

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether metformin can prevent or delay T2DM and its complications in people with increased risk of developing T2DM is unknown.To assess the effects of metformin for the prevention or delay of T2DM (...) ; P = 0.83; 2833 participants, 5 trials; very low-quality evidence); incidence of T2DM was 324/1751 versus 529/1881 participants (RR 0.50, 95% CI 0.38 to 0.65; P < 0.001; 3632 participants, 12 trials; moderate-quality evidence); the reporting of SAEs was insufficient and diverse and meta-analysis could not be performed (reported numbers were 4/118 versus 2/191; 309 participants; 4 trials; very low-quality evidence); cardiovascular mortality was 1/1073 versus 4/1082 (2416 participants; 2 trials

2019 Cochrane

276. Type 2 Diabetes Mellitus and Heart Failure Full Text available with Trip Pro

-1 receptor agonists if no recent HF decompensation) could be considered, but use with caution; may require dose adjustment DM indicates diabetes mellitus; DPP-4, dipeptidyl peptidase-4; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SGLT-2, sodium glucose cotransporter type 2; and TZDs, thiazolidinedione drugs. Figure 3 (...) with either GLP-1 receptor agonists or DPP-4 inhibitors compared with other glucose-lowering therapies. Additional data are still needed to determine whether there is, in fact, a higher risk of HF with DPP-4 inhibitors in individuals with DM. Some additional information could come from the CARMELINA trial (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus; URL: . Unique identifier: NCT01897532), which compares linagliptin versus placebo

2019 American Heart Association

277. Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 August 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG (...) Reports – Commission No. A19-49 Empagliflozin/linagliptin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-49 Version 1.0 Empagliflozin/linagliptin (type 2 diabetes mellitus) 29 August 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Empagliflozin/linagliptin (type 2 diabetes mellitus) – Benefit assessment according

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

278. Metformin hydrochloride / saxagliptin / dapagliflozin (Qtrilmet) - type 2 diabetes

Metformin hydrochloride / saxagliptin / dapagliflozin (Qtrilmet) - type 2 diabetes Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/521799/2019 EMEA/H/C/004910 Qtrilmet (...) (metformin / saxagliptin / dapagliflozin) An overview of Qtrilmet and why it is authorised in the EU What is Qtrilmet and what is it used for? Qtrilmet is a diabetes medicine that contains the active substances metformin, saxagliptin and dapagliflozin. It is used to treat type 2 diabetes in: • adults whose blood sugar is not controlled well enough with metformin combined with either saxagliptin or dapagliflozin (including those also taking a sulphonylurea, another type of diabetes medicine); • adults who

2019 European Medicines Agency - EPARs

279. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial Full Text available with Trip Pro

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium-glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin.Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end (...) at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product -4.7 vs. -3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide.Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide

2019 EvidenceUpdates

280. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial Full Text available with Trip Pro

. 7.1% with placebo; mostly mild to moderate).Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.© 2019 by the American Diabetes Association. (...) Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin.Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double

2019 EvidenceUpdates